OSE Immunotherapeutics Statistics

Total Valuation

OSE Immunotherapeutics has a market cap or net worth of EUR 153.58 million. The enterprise value is 121.72 million.

Market Cap	153.58M
Enterprise Value	121.72M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

OSE Immunotherapeutics has 21.75 million shares outstanding. The number of shares has increased by 22.97% in one year.

Current Share Class	n/a
Shares Outstanding	21.75M
Shares Change (YoY)	+22.97%
Shares Change (QoQ)	+22.87%
Owned by Insiders (%)	21.30%
Owned by Institutions (%)	1.19%
Float	16.33M

Valuation Ratios

The trailing PE ratio is 3.51 and the forward PE ratio is 2.25.

PE Ratio	3.51
Forward PE	2.25
PS Ratio	1.79
PB Ratio	1.89
P/TBV Ratio	1.89
P/FCF Ratio	2.63
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.27, with an EV/FCF ratio of 2.09.

EV / Earnings	2.64
EV / Sales	1.46
EV / EBITDA	2.27
EV / EBIT	2.26
EV / FCF	2.09

Financial Position

The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.54.

Current Ratio	4.93
Quick Ratio	4.70
Debt / Equity	0.54
Debt / EBITDA	0.82
Debt / FCF	0.75
Interest Coverage	18.48

Financial Efficiency

Return on equity (ROE) is 88.54% and return on invested capital (ROIC) is 35.12%.

Return on Equity (ROE)	88.54%
Return on Assets (ROA)	30.41%
Return on Capital (ROIC)	35.12%
Revenue Per Employee	1.60M
Profits Per Employee	885,231
Employee Count	55
Asset Turnover	0.75
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +73.04% in the last 52 weeks. The beta is 0.90, so OSE Immunotherapeutics's price volatility has been similar to the market average.

Beta (5Y)	0.90
52-Week Price Change	+73.04%
50-Day Moving Average	8.93
200-Day Moving Average	7.33
Relative Strength Index (RSI)	30.23
Average Volume (20 Days)	142,562

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OSE Immunotherapeutics had revenue of EUR 83.44 million and earned 46.03 million in profits. Earnings per share was 2.01.

Revenue	83.44M
Gross Profit	83.44M
Operating Income	53.84M
Pretax Income	49.44M
Net Income	46.03M
EBITDA	52.96M
EBIT	53.84M
Earnings Per Share (EPS)	2.01

Full Income Statement

Balance Sheet

The company has 75.75 million in cash and 43.89 million in debt, giving a net cash position of 31.86 million or 1.46 per share.

Cash & Cash Equivalents	75.75M
Total Debt	43.89M
Net Cash	31.86M
Net Cash Per Share	1.46
Equity (Book Value)	81.45M
Book Value Per Share	3.74
Working Capital	68.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 58.36 million and capital expenditures -34,000, giving a free cash flow of 58.32 million.

Operating Cash Flow	58.36M
Capital Expenditures	-34,000
Free Cash Flow	58.32M
FCF Per Share	2.68

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 64.52% and 55.17%.

Gross Margin	100.00%
Operating Margin	64.52%
Pretax Margin	59.25%
Profit Margin	55.17%
EBITDA Margin	63.46%
EBIT Margin	64.52%
FCF Margin	69.90%

Dividends & Yields

OSE Immunotherapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.97%
Shareholder Yield	-22.97%
Earnings Yield	28.53%
FCF Yield	37.98%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

OSE Immunotherapeutics has an Altman Z-Score of 3.94.

Altman Z-Score	3.94
Piotroski F-Score	n/a